“…After screening and qualification evaluation, 23 clinical trials involving 6,241 patients were finally included after excluding review articles, case reports, and meta-analysis articles, with the flow chart of literature selection shown in Figure 1 . Of the 23 studies, there were 12 phase II, 11 phase III, and 1 phase IV trials, with the year of publication ranging from 2005 to 2020 ( Table 1 ) ( Miller et al, 2005 ; Heymach et al, 2008 ; Goss et al, 2010 ; Mok et al, 2011 ; Rugo et al, 2011 ; Baselga et al, 2012 ; Kato et al, 2012 ; Johnston et al, 2013 ; Laurie et al, 2014 ; Liu et al, 2014 ; Mackey et al, 2015 ; Rini et al, 2016 ; Baselga et al, 2017 ; Kubota et al, 2017 ; Yan et al, 2017 ; Dummer et al, 2018 ; Lu et al, 2018 ; Liu et al, 2019 ; Nakagawa et al, 2019 ; Cortot et al, 2020 ; Guo et al, 2020 ; Sinn et al, 2020 ; Tao et al, 2020 ). According to the published Common Terminology Criteria for Adverse Events (CTCAE) by the National Cancer Institute (NCI), hypertension caused by anti-cancer treatment includes 5 grades of grade 1–5 ( Table 2 ) ( National Cancer Institute, 2017 ).…”